Robotic Extended Pelvic Lymphadenectomy for Intermediate- and High-Risk Prostate Cancer

被引:50
|
作者
Yuh, Bertram E. [1 ]
Ruel, Nora H. [1 ]
Mejia, Rosa [1 ]
Wilson, Chelsea M. [1 ]
Wilson, Timothy G. [1 ]
机构
[1] City Hope Natl Canc Ctr, Duarte, CA 90017 USA
关键词
Pelvic lymphadenectomy; Robotics; Positive lymph nodes; Prostate Cancer; LYMPH-NODE DISSECTION; RADICAL PROSTATECTOMY; IMPACT; METASTASES; MEN; YIELD;
D O I
10.1016/j.eururo.2012.01.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Accurate staging of prostate cancer is enhanced by a thorough evaluation of the pelvic lymph nodes. Limited data are available regarding robotic extended pelvic lymphadenectomy (PLA) in this setting. Objective: Analyze our experience performing robotic extended PLA. Design, setting, and participants: A total of 143 consecutive men with intermediate-or high-risk clinically localized adenocarcinoma of the prostate underwent robotic extended PLA and radical prostatectomy between September 2010 and November 2011 by a single surgeon. Surgical procedure: Lymph node packets were sent separately from bilateral common, external, and internal iliacs, obturators, node of Cloquet, and anterior prostatic fat. Measurements: Descriptive statistics were used to summarize lymph node yields and positive nodes. Clinical variables were examined in logistic regression models to predict lymph node positivity. Results and limitations: Median lymph node yield was 20 (range: 9-65, interquartile range: 15-25). Eighteen patients (13%) were found to have metastatic prostate cancer in the lymph nodes. The mean number of positive nodes foundwas 2.9 (range: 1-11). In 14 of 18 node-positive patients (78%), the extent of nodal invasion was outside the boundaries of a limited PLA. For four patients with positive nodes (22%), prostate biopsy predicted unilateral disease but PLA revealed contralateral positive lymph nodes. A total of 82% of patients experienced no complications, and most Clavien grade 1-2 complications consisted of anastomotic leakage, urinary retention, ileus, and lymphocele. Only 4% of patients experienced a grade 3 complication. Under multivariate regression analysis, prostate-specific antigen (PSA), clinical stage, and maximum biopsy core tumor volume were identified as significant predictors of finding positive pelvic lymph nodes (area under the curve: 91%). The main limitations include short follow-up and lack of randomization. Conclusions: Robotic extended bilateral PLA for prostate cancer up to the common iliac bifurcation increases nodal yield and positive nodal rate and can be performed safely. PSA, clinical stage, and maximum biopsy core volume are predictors for lymph node invasion. Long-term follow-up is needed to evaluate for therapeutic benefit. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
引用
收藏
页码:1004 / 1010
页数:7
相关论文
共 50 条
  • [41] A Specific Mapping Study Using Fluorescence Sentinel Lymph Node Detection in Patients with Intermediate- and High-risk Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection
    Nguyen, Daniel P.
    Huber, Philipp M.
    Metzger, Tobias A.
    Genitsch, Vera
    Schudel, Hans H.
    Thalmann, George N.
    EUROPEAN UROLOGY, 2016, 70 (05) : 734 - 737
  • [42] Preliminary Outcomes for Treatment of High Intermediate- and High-risk Prostate Cancer Patients using Pelvic Intensity Modulated Radiotherapy with Hypofractionated Simultaneous Integrated Boost to Prostate
    Reddy, K.
    Nelson, B. C.
    McCammon, R.
    Rusthoven, K. E.
    Newman, F.
    Kavanagh, B.
    Raben, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S376 - S376
  • [43] Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer
    Wyler, Stephen F.
    Sulser, Tullio
    Seifert, Hans-Helge
    Ruszat, Robin
    Forster, Thomas H.
    Gasser, Thomas C.
    Bachmann, Alexander
    UROLOGY, 2006, 68 (04) : 883 - 887
  • [44] Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E250 - E250
  • [45] Brachytherapy Increased use in patients with intermediate- and high-risk prostate cancers
    Ali, Sanna
    Esper, Peg
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2021, 25 (03) : 321 - 328
  • [46] Intermediate- and high-risk melanoma.
    Agarwala S.S.
    Current Treatment Options in Oncology, 2002, 3 (3) : 205 - 217
  • [47] Outcomes of High-Dose Rate Brachytherapy for Intermediate- to High-Risk Prostate Cancer at One Institution
    Lin, E. Y.
    Lee, A.
    Demanes, J.
    Kamrava, M.
    Venkat, P. S.
    Hagio, M. A.
    Zaide, L. B.
    Park, S. J.
    Zarate, C.
    Chang, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E927 - E927
  • [48] Quantitative imaging parameters to predict local staging of prostate cancer in intermediate- to high-risk patients
    Laudicella, R.
    Skawran, S.
    Ferraro, D. A.
    Muhlematter, U.
    Maurer, A.
    Grunig, H.
    Donati, O.
    Eberli, D.
    Burger, I. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S206 - S206
  • [49] Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy
    J V Hegde
    D J Margolis
    P-C Wang
    R E Reiter
    J Huang
    M L Steinberg
    M Kamrava
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 241 - 248
  • [50] Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients
    Laudicella, Riccardo
    Skawran, Stephan
    Ferraro, Daniela A.
    Muhlematter, Urs J.
    Maurer, Alexander
    Grunig, Hannes
    Ruschoff, Hendrik J.
    Rupp, Niels
    Donati, Olivio
    Eberli, Daniel
    Burger, Irene A.
    INSIGHTS INTO IMAGING, 2022, 13 (01)